

## CRMO/SAPHO Workgroups:

Runs discussion in small workgroup

Presents and discusses results in big group after the small group session

On Wednesday and Thursday afternoon we will have 2 big group discussions, one on the clinical and one the biomarker outcomes. In order to avoid redundancy with repeating outcomes in the one single group which is formed to discuss a clinical trial design, we would like for the individual highlighted in green to present the respective big group discussions to the other big group. After the mutual update on the respective discussion in the "other" big group, the session on clinical trial design will be started.

Representative of "clinical big group" who presents to "biomarker big group" and representative of "biomarker big group" who presents to "clinical big group"

### WEDNESDAY AFTERNOON 9/3/08, 2:30pm to 5pm:

Small group discussions are from 2:30pm to 3:30pm

Big group discussions are from 3:30pm to 4:30pm

#### 7 Small Workgroups:

##### 1. CLINICAL TRIAL ENTRY CRITERIA (AUDITORIUM)

C Wallace

Laxer

Ozen

Barron

Miettunen

##### 2. CLINICAL RHEUM and REHAB ENDPOINTS (CHAPEL)

Giannini

Inman

Lehman

Paul

Ward

Dancey

Goldbach-Mansky

(rehab representatives)

##### 3. BONE IMAGING (CLASSROOM 162A)

Khanna

Job-Deslandre

Hill

Yao

Chen, Clara?

Reynolds

4. SKIN SCORING (**CLASSROOM 162 B**)

Cowen

Fuhlbrigge

Turner

5. GASTROINTESTINAL EVALUTION (**BALCONY**)

Strober

Ishigatsubo

Douek

Kelsall

6. BONE MARKERS (**FOYER**)

Novack

Ferguson

Collins

Uzel

7. INFLAMMATORY/GENETIC MARKERS (**RATHSKELLER**)

Kastner

Wallace G

El-Shanti

Holland

Colbert

Aksentjevich

Elaine

Gordon

Siegel

**2 BIG GROUPS:**

CLINICAL: (**AUDITORIUM**)

Giannini

Ron Laxer

Bone imaging

Skin scoring

Entry criteria

Rheum and rehab outcomes

BIOMARKER: (**RATHSKELLER**)

El-Shanti

Dan Kastner

Inflammation

Bone

GI

# BEHCET'S DISEASE Workgroups:

**THURSDAY AFTERNOON 9/4/08, 2:30pm to 5pm:**

**Small group discussions are from 2:30pm to 3:30pm**

**Big group discussions are from 3:30pm to 4:30pm**

## **6 Small Workgroups:**

### **1. CLINICAL TRIAL ENTRY CRITERIA (AUDITORIUM)**

Wallace C

Yazici H

Yazici, Y

Seyahi

Rider

Lehman

Uzel

### **2. CLINICAL RHEUM AND REHAB ENDPOINTS (CHAPEL)**

Giannini

Ozen

Paul

Ward

Goldbach-Mansky

Dancey

(rehab representatives)

### **3. SKIN AND MUCOSAL SCORING GROUP (CLASSROOM 162A)**

Turner

Fuhlbrigge

Cowen

Stratton

Nikolov

Zouboulis?

### **4. VASCULAR AND GASTROENTERAL MANIFESTATIONS AND BIOMARKERS (CLASSROOM 162B)**

(GI was likely discussed in the Wednesday session on GI manifestations in CRMO/SAPHO may therefore concentrate on vascular manifestations)

Laxer

Ishigatsubo

Barron

Chen, vascular imaging?

### **5. INFLAMMATORY MARKERS (RATHSKELLER)**

Colbert

Kastner

Wallace G  
Holland  
Siegel  
Gadina

#### 6. GENETICS GROUP (FOYER)

Aksentjevich

Gul

Remmers  
Kone-Paut  
Ferguson  
El-Shanti

#### **2 BIG GROUPS:**

##### CLINICAL: (AUDITORIUM)

Giannini

Yazici Y

Skin and mucosal scoring  
Entry criteria  
Rheum and rehab outcomes

##### BIOMARKER: (RATHSKELLER)

Wallace C

Ahmet Gul

Vascular  
GI  
Inflammatory

#### **FRIDAY MORNING WORKSHOPS 9/05/08, 9:45am to 12 noon:**

**Small group discussions are from 9:45am to 11:00am**

**Big group discussion is from 11:00am to 12:00noon**

#### **3 Small Workgroups:**

##### 1. SKIN AND MUCOSAL IMMUNOLOGY (Friday) (CLASSROOM 162 A)

Zouboulis

Lowe

Gordon  
Wallace G  
Lee R  
Cowen  
Turner

2. OPHTHALMOLOGICAL EVALUATION (Friday) **(CLASSROOM 162 B)**

Bodaghi

Sen

Tugal-Tutkun

Wallace G

Nussenblatt??

J Smith

3. ASSESSING "UNMET NEEDS" IN BEHCET'S DISEASE-INSIGHTS FROM RCT

Yazici H

Gul

Yazici Y

Kone-Paut

Job-Deslandre

Seyahi

4. LOGISTICS OF SHARING CLINICAL AND BIOMARKER DATA AND STUDY PROCEDURES **(AUDITORIUM)**

Giannini

Fuhlbrigge

Ferguson

Wallace C

Ozen

Rider

Colbert

Dancey

Goldbach-Mansky

Serrate-Sztejn?

**1 BIG GROUP: (AUDITORIUM)**

Giannini

Wallace C

All groups

SKIN IMMUNOLOGY

OPHTHALMOLOGICAL EVALUATION

SHARING CLINICAL AND BIOMARKER DATA, STUDY PROCEDURES AND CONDUCTING CLINICAL TRIALS